Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

sargramostim

A recombinant therapeutic agent which is chemically identical to or similar to endogenous human GM-CSF. Binding to specific cell surface receptors, sargramostim modulates the proliferation and differentiation of a variety of hematopoietic progenitor cells with some specificity towards stimulation of leukocyte production and may reverse treatment-induced neutropenias. This agent also promotes antigen presentation, up-regulates antibody-dependent cellular cytotoxicity (ADCC), and increases interleukin-2-mediated lymphokine-activated killer cell function; it may also augment host antitumoral immunity.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:23-L-leucine colony-stimulating factor 2
colony stimulating factor 2
CSF-2
GM-CSF
granulocyte macrophage colony-stimulating factor
sargramostatin
US brand name:Leukine
Prokine
Abbreviation:GM CSF
GM-CSF
rhu GM-CFS
Code name:DRG-0012
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search